Social Media Press Releases

RSS

Showing Press Releases with Tag: respiratory tract infection

1/29/2010

PIVOTAL TRIAL RESULTS FOR MOTAVIZUMAB PUBLISHED IN CURRENT ISSUE OF PEDIATRICS

» read more
6/29/2009

MedImmune Funds Study to Help Gain Insights Into Full Burden of RSV Disease Among Premature Infants

» read more
6/29/2009

MedImmune Expands Access for Eligible Premature Infants to Receive Synagis(R) at No Cost

» read more
10/24/2008

MedImmune to Present Nine Abstracts on RSV and Influenza at 48th Annual ICAAC/46th Annual IDSA Meeting

» read more
10/11/2008

MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease

» read more
5/05/2008

Study Shows Physician Judgment is Important in Reducing Rate of RSV-Related Hospitalizations Among High-Risk Infants

» read more
5/04/2008

Phase 3 Data Regarding Anti-RSV Antibody To Be Presented at Pediatric Academic Societies (PAS) Annual Meeting

» read more
4/28/2008

Fourteen Abstracts Featuring MedImmune’s Influenza and RSV Therapeutic Areas to Be Presented at Pediatric Academic Societies Annual Meeting

» read more
2/19/2008

Neonatologists and Pediatricians Highlight Progress and Barriers to Preemie Care

» read more
2/04/2008

MedImmune Submits Biologics License Application to FDA for Motavizumab

» read more
10/29/2007

MedImmune Presents New Pharmaco-Economic Data at American Academy of Pediatrics Regarding Infants at High Risk for RSV

» read more
10/26/2007

MedImmune to Present RSV Surveillance and Cost-Effectiveness Data at American Academy of Pediatrics National Conference & Exhibition

» read more
10/09/2007

Data from MedImmune Infectious Disease Clinical Programs Presented at European Society for Paediatric Research Annual Meeting

» read more
10/04/2007

MedImmune Announces Phase 2 Safety Data for Anti-RSV Antibody and National RSV Surveillance Results

» read more
8/23/2007

MedImmune’s Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study

» read more